Archer Materials (ASX:AXE) - CEO, Mohammad Choucair (left)
CEO, Mohammad Choucair (left)
Source: Archer Materials
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Archer Materials (AXE) has expanded its commercial access to institutional deep-technology infrastructure
  • Archer will gain access to the University of Sydney’s ‘world-class’ analytical facilities as well as to specialist instruments for chemical and biological imaging
  • CEO Dr Mohammad Choucair says Archer is pleased to have secured access which would otherwise be too expensive to purchase and operate alone
  • Ultimately, the company aims to become a key developer of biochips for the medical diagnostics industry
  • Archer is up 2.33 per cent and shares are trading at 88 cents

Archer Materials (AXE) has expanded its commercial access to institutional deep-technology infrastructure.

The material technology company considers this to be a pivotal step in developing its biochip technology.

Specifically, Archer will have direct access to ‘world-class’ analytical facilities, including one of the University of Sydney’s core research facilities.

In addition, Archer will also have access to specialist instruments and facilities such as multi-million-dollar advanced spectrometers for chemical and biological imaging at the nanoscale and protein production facilities in ‘state-of-art’ labs.

“We are very pleased to secure access to world-class facilities that would otherwise be extremely costly to purchase and operate ourselves,” CEO Dr Mohammad Choucair said.

Having this access allows the company to qualify its production processes as it advances towards sub-10 nanometres (nm) biochip feature sizes. For reference, one nanometre is a billionth of one metre.

The miniaturising process began earlier this month and is part of Archer’s goal of becoming a key developer of biochips for the medical diagnostics industry.

To successfully develop its biochip, Archer needs to analyse components of semiconductor device materials and establish quality control processes at the nanoscale. This is because Archer’s biochip technology uses materials like graphene.

“Archer’s growth has involved integrating the company’s early-stage tech development within institutional scale operations and this ultimately translates to maintaining a strong cash position and no corporate debt,” he concluded.

Archer is up 2.33 per cent and shares are trading at 88 cents at 10:35 am AEST.

AXE by the numbers
More From The Market Herald
Gratify (ASX:GTI) - Executive Chairman, Iain Dunstan

" Gratifii (ASX:GTI) sees revenue growth for third consecutive quarter

Loyalty and rewards company Gratifii (ASX:GTI) has seen its revenue growth exceed the forecast for the…
Linius Technologies (ASX:LNU) - Incoming CEO, James Brennan

" Linius Technologies (ASX:LNU) undertakes share placement to support growth plans

Linius Technologies (ASX:LNU) undertakes share placement to support growth plans
Weebit Nano (ASX:WBT) - CEO, Coby Hanoch

" Weebit Nano (ASX:WBT) nearing commercialisation

Weebit Nano (ASX:WBT) says it made significant in-roads towards commercialisation during its December quarter which was…
Delta Drone International (ASX:DLT) - CEO, Christopher Clark

" Delta Drone (ASX:DLT) selling drone safety business

Delta Drone International (ASX:DLT) has signed a deal to sell its drone safety business.